Tianjin TEDA Biomedical Engineering Company Limited
Symbool: 8189.HK
HKSE
0.068
HKDMarktprijs vandaag
-5.7818
Koers/Winst Verhouding
0.0135
Koers/Winst Groei Verhouding
118.41M
MRK Kapitalisatie
- 0.00%
DIV Rendement
Tianjin TEDA Biomedical Engineering Company Limited (8189-HK) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 5.9 | 9.5 | 29.8 | |||||||||||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.net-receivables | 0 | 8.8 | 31.9 | 32.1 | |||||||||||||||||||
balance-sheet.row.inventory | 0 | 90.5 | 74 | 75.2 | |||||||||||||||||||
balance-sheet.row.other-current-assets | 0 | 85.2 | 80.3 | 75 | |||||||||||||||||||
balance-sheet.row.total-current-assets | 0 | 190.3 | 193.1 | 208.7 | |||||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 99.7 | 118.5 | 125 | |||||||||||||||||||
balance-sheet.row.goodwill | 0 | 0 | 5.5 | 0 | |||||||||||||||||||
balance-sheet.row.intangible-assets | 0 | 13.3 | 20.1 | 13.9 | |||||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 13.3 | 25.6 | 13.9 | |||||||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | -144.1 | -138.8 | |||||||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 112.9 | 144.1 | 138.8 | |||||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.total-assets | 0 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.account-payables | 0 | 16.1 | 20.7 | 29.5 | |||||||||||||||||||
balance-sheet.row.short-term-debt | 0 | 63.3 | 60.8 | 45.1 | |||||||||||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 3.1 | 1.5 | |||||||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 20.3 | 35.2 | 45.2 | |||||||||||||||||||
Deferred Revenue Non Current | 0 | -1.6 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||||||
balance-sheet.row.other-current-liab | 0 | 13.4 | 136.7 | 117.4 | |||||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 21.9 | 35.2 | 45.2 | |||||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 11.9 | 39.2 | 42.9 | |||||||||||||||||||
balance-sheet.row.total-liab | 0 | 238.7 | 253.5 | 237.2 | |||||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 3.7 | 16.8 | 16.8 | |||||||||||||||||||
balance-sheet.row.common-stock | 0 | 189.4 | 189.4 | 189.4 | |||||||||||||||||||
balance-sheet.row.retained-earnings | 0 | -401.7 | -379 | -350.9 | |||||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | -16.8 | -16.8 | -16.8 | |||||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 275.3 | 262.2 | 262.2 | |||||||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 50 | 72.7 | 100.8 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 303.3 | 337.2 | 347.6 | |||||||||||||||||||
balance-sheet.row.minority-interest | 0 | 14.6 | 11 | 9.6 | |||||||||||||||||||
balance-sheet.row.total-equity | 0 | 64.6 | 83.7 | 110.4 | |||||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||||||
Total Investments | 0 | 0 | 2.7 | 3.3 | |||||||||||||||||||
balance-sheet.row.total-debt | 0 | 83.6 | 96 | 90.3 | |||||||||||||||||||
balance-sheet.row.net-debt | 0 | 77.6 | 89.2 | 63.9 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -26.5 | -44.8 | -50 | ||||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 15.4 | 9.5 | 7.1 | ||||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | -1.7 | -5.3 | 43.5 | ||||||||||||||||||
cash-flows.row.account-receivables | 0 | -2.1 | 0.1 | -4.3 | ||||||||||||||||||
cash-flows.row.inventory | 0 | 1.2 | 16.4 | -2.7 | ||||||||||||||||||
cash-flows.row.account-payables | 0 | 2.1 | -0.1 | 4.3 | ||||||||||||||||||
cash-flows.row.other-working-capital | 0 | -3 | -21.8 | 46.2 | ||||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 0 | 34 | 35.4 | ||||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.acquisitions-net | 0 | -6.4 | 1.1 | 1.1 | ||||||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -22.8 | -22 | ||||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0.7 | 43.8 | -1.9 | ||||||||||||||||||
cash-flows.row.other-investing-activites | 0 | 1.5 | 3 | 10.3 | ||||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | -12.9 | -8.5 | -26.5 | ||||||||||||||||||
cash-flows.row.debt-repayment | 0 | -46.8 | -16 | -31.2 | ||||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.other-financing-activites | 0 | 53 | 44.1 | 11 | ||||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 6.2 | 28.1 | -20.2 | ||||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | ||||||||||||||||||
cash-flows.row.net-change-in-cash | 0 | -19.6 | 12.9 | -10.7 | ||||||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 6.9 | 26.4 | 13.5 | ||||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 26.4 | 13.5 | 24.2 | ||||||||||||||||||
cash-flows.row.operating-cash-flow | 0 | -12.8 | -6.7 | 36 | ||||||||||||||||||
cash-flows.row.capital-expenditure | 0 | -8.8 | -33.7 | -14 | ||||||||||||||||||
cash-flows.row.free-cash-flow | 0 | -21.6 | -40.4 | 22 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 398 | 449.7 | 476.4 | |||||||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 376.6 | 433.3 | 430.8 | |||||||||||||||||||
income-statement-row.row.gross-profit | 0 | 21.4 | 16.4 | 45.6 | |||||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-expenses | 0 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.operating-expenses | 0 | 31.2 | 38.5 | 51.8 | |||||||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 407.8 | 471.8 | 482.5 | |||||||||||||||||||
income-statement-row.row.interest-income | 0 | 0.2 | 0.8 | 0.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -0.3 | -0.1 | -0.5 | |||||||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 7.3 | -5.7 | -40.4 | |||||||||||||||||||
income-statement-row.row.interest-expense | 0 | 5.2 | 6.4 | 5.5 | |||||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 11.6 | 15.4 | 9.5 | |||||||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||||||
income-statement-row.row.operating-income | 0 | -19.3 | -20.8 | -4.4 | |||||||||||||||||||
income-statement-row.row.income-before-tax | 0 | -12 | -26.5 | -44.8 | |||||||||||||||||||
income-statement-row.row.income-tax-expense | 0 | -1 | 0.2 | -0.1 | |||||||||||||||||||
income-statement-row.row.net-income | 0 | -20.2 | -26.6 | -44.8 |
Vaak gestelde vragen
Wat is Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) totale activa?
Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) totale activa is 303277966.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is N/A.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.054.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.055.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.045.
Wat is Tianjin TEDA Biomedical Engineering Company Limited (8189.HK) nettowinst (netto-inkomen)?
De nettowinst is -20159658.000.
Wat is de totale schuld van het bedrijf?
De totale schuld is 83557328.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 31200528.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 0.000.